Barclays Reiterates Buy Rating on 10x Genomics with $40 Target
Barclays analyst Luke Sergott maintains a buy rating on 10x Genomics, setting a $40 price target, a 9.42% upside from the current price.
Key Points
- Barclays reiterated its buy rating for 10x Genomics, Inc. (TXG) with a price target of $40, as announced on June 24, 2026.
- Barclays's $40 price target implies 9.42% upside from 10x Genomics, Inc.'s ($TXG) current $36.55 share price.
- Shares of TXG traded at $33.98 on Wednesday, with a market cap of $4.18 billion and a forward P/E of 164.7.
- FMR LLC increased its stake in 10x Genomics by 48.9%, holding 17.74 million shares valued at $376.64 million.
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
Barclays has reiterated its buy rating on 10x Genomics, Inc. (NasdaqGS: TXG), setting a price target of $40. Analyst Luke Sergott shared this update on June 24, 2026, suggesting continued confidence in the company's prospects.
Barclays vs. the S&P 500
Hypothetical, simulated performance of disclosed positions vs. the S&P 500. Not realized profit and not investment advice. Past performance does not indicate future results. Details.
Other Institutional Activity in 10x Genomics
FMR LLC grew its holdings by 5.82 million shares, ending with 17.74 million shares worth about $376.64 million. ARK Investment Management LLC reduced its position by 950,052 shares, now holding 11.72 million shares valued at approximately $248.76 million, a decrease of 7.5%. BlackRock, Inc. added 65,451 shares, bringing its total to about 10.08 million shares valued at $213.99 million, a modest increase of 0.7%. Vanguard Portfolio Management LLC opened a new position with 6.91 million shares worth $146.76 million.
10x Genomics, Inc. Stock Down 40.6%
Shares of 10x Genomics traded near $33.98 on Wednesday. The company has a market cap of $4.18 billion, a forward P/E ratio of 164.7, and a beta of 2.114. The stock's 52-week range is between $10.48 and $36.59, with a 50-day moving average of $25.33 and a 200-day moving average of $19.10. The company maintains a strong liquidity position with a current ratio of 5.90 and a quick ratio of 5.25, while its debt-to-equity ratio stands at 10.0.
$TXG price target
Past daily closes and this analyst's 12-month price target. Not investment advice.
Recent Earnings
10x Genomics reported revenue of $638.78 million, experiencing a slight decline in revenue growth by 2.6%. The company is not yet profitable, with a net margin of -3.55% and a return on equity of -2.98%. The next earnings report is scheduled for August 6, 2026.
Analysts Set New Price Targets
On June 24, 2026, Barclays maintained a buy rating on 10x Genomics with a $40 price target. Other analysts have varied views: Morgan Stanley and JP Morgan both maintained hold ratings with targets of $22 and $20, respectively, on May 12, 2026. Canaccord Genuity reiterated a buy rating with a $32 target on April 20, 2026. The consensus rating is a buy, with a mean target price of $26.85 based on 13 analyst opinions.
About 10x Genomics, Inc.
10x Genomics, Inc. is a healthcare company based in Pleasanton, California. It specializes in developing and selling tools for analyzing biological systems. The company offers platforms like Chromium and Visium, which are used in single-cell and spatial analysis. 10x Genomics serves academic, government, and biopharmaceutical institutions and is led by CEO Dr. Serge Saxonov.
Bottom Line
Barclays' reiteration of its buy rating on 10x Genomics with a $40 target reflects optimism about the company's future. Institutional interest remains strong, with significant activity among major funds. Investors will be watching the upcoming earnings report for further insights into the company's performance.
Get 10x Genomics, Inc. alerts
New 13F filings, insider trades, and analyst moves on $TXG, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.